Fatty liver and hyperlipidemia in a cohort of HIV-positive africans on highly active antiretroviral therapy

Journal of the National Medical Association

Volumn 101, Issue 2, 2009, Pages 151-155

  Lesi, Olufunmilayo A ^a   Soyebi, Kofoworola S ^a   Eboh, Cosmas N ^a  

^a LAGOS UNIVERSITY TEACHING HOSPITAL   (Nigeria)

Author keywords

HIV AIDS; Hyperlipidemia; Liver

Indexed keywords

ALANINE AMINOTRANSFERASE; EMTRICITABINE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LAMIVUDINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEVIRAPINE; STAVUDINE; TENOFOVIR; TRIACYLGLYCEROL; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; DEMOGRAPHY; DISEASE ASSOCIATION; ECHOGRAPHY; FATTY LIVER; FEMALE; HEPATOMEGALY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; NIGERIA; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 65249125741     PISSN: 00279684     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0027-9684(15)30828-2     Document Type: Article

References (27)

1. Adams LA, Angulo P, Lindor KD. Nonalcoholic fatty liver disease. CMAJ. 2005;172:899-905.
2. Ristig M, Drechsler H, Powderly WG. Hepatic steatosis and HIV infection. AIDS Patient Care STDS. 2005; 19:356-365.
3. Day CP. Non-alcoholic fatty liver disease: Current concepts and management strategies. Clin Med. 2006;6:19-25.
4. Brunt EM. Non alcoholic fatty liver disease. Sem Liver Dis. 2004;1:3-20.
5. McGovern BH, Ditelberg JS, Taylor LE, et al. Hepatic steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infection in HIV-seropositive patients. Clin Infect Dis. 2006;43:373-376.
6. Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: A collaborative analysis of prospective studies. Lancet. 2002;360:119-129.
7. Pallella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med.l998;338:853-860.
8. Miller KD, Cameron M, Wood LV, Dalakas MC, et al. Lactic acidosis and hepatic steatosis associated with use of stavudine: A report of four cases. Ann Intern Med. 2000;133:192-196.
9. Sweet DE. Metabolic complications of antiretroviral therapy. Top HIV Med. 2005;13:70-74.
10. Caldwell SH, Swerdlow RH, Khan EM, et al. Mitochondrial toxicities in non-alcoholic fatty liver disease. J Hepatol. 1999;31:430-434.
11. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. The JNC 7 Report. JAMA. 2003;289:2560-2572.
12. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: The Evidence Report. Washington, DC: Government Printing Office; 1998. US Department of Health and Human services publication. NIH. 98-4083.
13. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001 ;285:2486-2497.
14. Hadigan C, Liebau J, Andersen R, et al. Magnetic Resonance Spectroscopy of hepatic lipid content and associated risk factors in HIV Infection. J Acquir Immune Defic Syndr. 2007;46:312-317.
15. Saadeh S, Younossi ZM, Remer EM, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology. 2002;123:745-750.
16. Ramalho F. Hepatitis C infection and liver steatosis. Antiviral Res. 2003;60:125-127.
17. Okany CC, Akanmo AS. Clinical manifestation of HIV/AIDS. Arch Ibadan Med. 2004;5:7-14.
18. Lesi OA, Kehinde MO, Oguh DN, et al. Hepatitis B and C Virus infection in Nigerian patients with HIV/AIDS. Nig Postgraduate Med J. 2007;14:129-133.
19. Ladep NG, Agbaji 0, Agaba P, et al. Does immunological status affect the prevalence of Hepatitis C virus infection among HIV/AIDS patients? Niger J Med. 2007;16:231-234.
20. Emokpae MA, Alabi P, Abubakar AG.Changes in lipids and routine haematological parameters as Human Immunodeficiency Virus (HIV) Infection progresses to Acquired Immunodeficiency Syndrome (AIDS). J Med Lab Sci. 2004; 13:23-29.
21. Filippini P, Scolastico C, Battaglia M, et al. Lipodystrophy and serum lipid abnormalities in HIV-positive sub-Saharan population on ART. J Infect. 2006;53:e29-e33.
22. Imarhiagbe FA, Kubeyinje EP. Hypertriglyceridemia in Antiretroviral Therapy. Med Gen Med. 2005;7:65.
23. Green M. Evaluation and management of Dyslipidaemia in patients with HIV infection. J Gen Intern Med. 2002; 17:797-810.
24. Fontas E, van Leth F, Sabin CA, et al. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? J Infect Dis. 2004;189:1056-1074.
25. Mondy K, Overton ET, Grubb J, et al. Metabolic Syndrome in HIV-infected Patients from an Urban, Midwestern US Outpatient Population. Clin Infect Dis. 2007;44:726-734.
26. Sanyan AJ, Campbell-Sargent C, Mirshahi F, et al. Nonalcoholic steato-hepatitis: Association of insulin resistance and mitochondrial abnormalities. Gastroenterology. 2001;120:1183-1192.
27. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofo-vir versus stavudine in combination therapy in antiretroviral-naive patients. JAMA. 2004;292:191-201.